These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37343227)

  • 1. Predicting a Stable Dimeric Form of the PD1-PDL1 Complex: Implications for Understanding the PD1 Activation Mechanism.
    Ponce LF; Ramírez-Echemendia DP; León K; Valiente PA
    J Phys Chem B; 2023 Jul; 127(26):5764-5771. PubMed ID: 37343227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling a Conserved Conformation of the FG Loop upon the Binding of Natural Ligands to the Human and Murine PD1.
    Ponce LF; Leon K; Valiente PA
    J Phys Chem B; 2022 Feb; 126(7):1441-1446. PubMed ID: 35167293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the conformational dynamics of PD1 in complex with different ligands: What we can learn for designing novel PD1 signaling blockers?
    Ponce LF; García-Martínez K; León K; Valiente PA
    Proteins; 2021 Feb; 89(2):141-148. PubMed ID: 32862461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations.
    Lyu N; Wang K; Zhang F; Qin H; Zhao Y; Wu R; Si Y; Wang L
    Phys Chem Chem Phys; 2020 Jan; 22(3):1276-1287. PubMed ID: 31850422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death 1 and programmed cell death ligand 1 expression in invasive breast carcinoma using CAL10 and NAT105 immunostaining.
    Durak Ö; Bozkurt KK; Çiriş İM; Kocer M; Eroğlu HE
    Biotech Histochem; 2023 Feb; 98(2):147-154. PubMed ID: 36281760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
    Zuazo M; Gato-Cañas M; Llorente N; Ibañez-Vea M; Arasanz H; Kochan G; Escors D
    Ann Transl Med; 2017 Oct; 5(19):385. PubMed ID: 29114543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.
    Xing X; Guo J; Ding G; Li B; Dong B; Feng Q; Li S; Zhang J; Ying X; Cheng X; Guo T; Du H; Hu Y; Zhou T; Wang X; Li L; Li Q; Xie M; Li L; Gao X; Shan F; Li Z; Jia S; Wen X; Wang J; Ji J
    Oncoimmunology; 2018; 7(3):e1356144. PubMed ID: 29399387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.
    Amarnath S; Mangus CW; Wang JC; Wei F; He A; Kapoor V; Foley JE; Massey PR; Felizardo TC; Riley JL; Levine BL; June CH; Medin JA; Fowler DH
    Sci Transl Med; 2011 Nov; 3(111):111ra120. PubMed ID: 22133721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer.
    Kaufman B; Abramov O; Ievko A; Apple D; Shlapobersky M; Allon I; Greenshpan Y; Bhattachrya B; Cohen O; Charkovsky T; Gayster A; Shaco-Levy R; Rouvinov K; Livoff A; Elkabets M; Porgador A
    Sci Adv; 2023 May; 9(21):eadg2809. PubMed ID: 37235664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.
    Tang X; Li Q; Zhu Y; Zheng D; Dai J; Ni W; Wei J; Xue Y; Chen K; Hou W; Zhang C; Feng X; Liang Y
    Am J Transl Res; 2015; 7(3):460-73. PubMed ID: 26045887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.
    Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
    Front Immunol; 2022; 13():862084. PubMed ID: 35493449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
    Lei Q; Wang D; Sun K; Wang L; Zhang Y
    Front Cell Dev Biol; 2020; 8():672. PubMed ID: 32793604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
    Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
    Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2.
    Taylor J; Bulek A; Gannon I; Robson M; Kokalaki E; Grothier T; McKenzie C; El-Kholy M; Stavrou M; Traynor-White C; Lim WC; Panagiotou P; Srivastava S; Baldan V; Sillibourne J; Ferrari M; Pule M; Thomas S
    Front Immunol; 2023; 14():1119350. PubMed ID: 37334382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
    Guo L; Bodo J; Durkin L; Hsi ED
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanobody against PDL1.
    Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
    Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.
    Haile ST; Dalal SP; Clements V; Tamada K; Ostrand-Rosenberg S
    J Immunol; 2013 Sep; 191(5):2829-36. PubMed ID: 23918985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction.
    Patil SP; Fattakhova E; Hofer J; Oravic M; Bender A; Brearey J; Parker D; Radnoff M; Smith Z
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
    Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
    J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.